当前位置： SCI文献检索 > Clinical Genitourinary Cancer期刊下所有文献 > Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.

Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.

Abstract：

BACKGROUND:There is a lack of molecularly-informed biomarkers for patients with metastatic renal cell carcinoma (RCC). Plasma cell-free DNA (cfDNA) sequencing is a minimally-invasive alternative to tissue for profiling the genome in other cancers but relevance in metastatic RCC remains unclear. MATERIALS AND METHODS:Whole blood was collected from 55 patients with metastatic RCC. Plasma cfDNA and leukocyte DNA were subjected to targeted sequencing across 981 cancer genes. Matched tumor tissue from 14 patients was analyzed. RESULTS:Thirty-three percent of patients had evidence for RCC-derived circulating tumor DNA (ctDNA), significantly lower than patients with metastatic prostate or bladder cancer analyzed using the same approach. Among ctDNA-positive patients, ctDNA fraction averaged only 3.9% and showed no strong association with clinical variables. In these patients, the most commonly mutated genes were VHL, BAP1, and PBRM1, and matched tissue concordance was 77%. Evidence of somatic expansions unrelated to RCC, such as clonal hematopoiesis of indeterminate potential, were detected in 43% of patients. Pathogenic germline mutations in DNA repair genes were detected in 11% of patients. CtDNA-positive patients had shorter overall survival and progression-free survival on first-line therapy. Patients with evidence of clonal hematopoiesis of indeterminate potential had an intermediate prognosis compared with ctDNA-positive and -negative patients. CONCLUSIONS:CfDNA sequencing enables straightforward characterization of the somatic RCC genome in a minority of patients with metastatic RCC. Owing to low ctDNA abundance, and the presence of non-RCC derived somatic clones in circulation, cfDNA sequencing may not be a simple pan-patient alternative to tissue biopsy in metastatic RCC.

journal_name

Clin Genitourin Cancer

journal_title

Clinical genitourinary cancer

authors

Bacon JVW,Annala M,Soleimani M,Lavoie JM,So A,Gleave ME,Fazli L,Wang G,Chi KN,Kollmannsberger CK,Wyatt AW,Nappi L

doi

10.1016/j.clgc.2019.12.018

subject

Has Abstract

pub_date

2020-08-01 00:00:00

pages

322-331.e2

issue

4

eissn

1558-7673

issn

1938-0682

pii

S1558-7673(19)30391-X

journal_volume

18

pub_type

杂志文章

相关文献

Clinical Genitourinary Cancer文献大全
  • Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.

    abstract：BACKGROUND:We investigated the activity of lenalidomide, which has antiangiogenic, antineoplastic, and immunomodulatory properties, in chemotherapy-naive, castration-resistant prostate cancer (CRPC) patients. PATIENTS:Patients received 25 mg/d lenalidomide for 21 days in 28-day cycles, until disease progression or una...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2013.09.001

    authors： Nabhan C,Patel A,Villines D,Tolzien K,Kelby SK,Lestingi TM

    更新日期：2014-02-01 00:00:00

  • A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.

    abstract：BACKGROUND:Tamoxifen (TAM) has been shown to be active against the bicalutamide-induced breast events (BEs) gynecomastia, and breast pain in patients with prostate cancer (PC). Optimal doses and schedules are not yet established. Debate still exists about whether prophylaxis with TAM is more effective than treatment of...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clgc.2012.03.002

    authors： Serretta V,Altieri V,Morgia G,Nicolosi F,De Grande G,Mazza R,Melloni D,Allegro R,Ferraù F,Gebbia V

    更新日期：2012-09-01 00:00:00

  • The current and emerging role of immunotherapy in prostate cancer.

    abstract：:Recent phase III trial results have demonstrated the effectiveness of sipuleucel-T, a therapeutic cancer vaccine, in the treatment of metastatic prostate cancer. Yet, despite the survival benefit of sipuleucel-T, questions remain about how immunologic agents can be used in the treatment of metastatic prostate cancer. ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CGC.2010.n.002

    authors： Madan RA,Gulley JL

    更新日期：2010-12-01 00:00:00

  • Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer.

    abstract：INTRODUCTION:The objective of this study was to examine the overall survival (OS) in patients diagnosed with high-grade T1 non-muscle-invasive bladder cancer treated with early radical cystectomy versus local treatment of the primary tumor, defined as endoscopic management with or without intravesical chemotherapy or i...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2020.03.013

    authors： Tully KH,Roghmann F,Noldus J,Chen X,Häuser L,Kibel AS,Sonpavde GP,Mossanen M,Trinh QD

    更新日期：2020-12-01 00:00:00

  • A phase II study of depsipeptide in refractory metastatic renal cell cancer.

    abstract：BACKGROUND:Therapeutic options for renal cell cancer are inadequate. Depsipeptide is a histone deacetylase inhibitor with promising preclinical and early clinical activity. PATIENTS AND METHODS:Patients with refractory renal cell cancer with normal organ function and no history of significant cardiovascular disease we...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.3816/CGC.2006.n.018

    authors： Stadler WM,Margolin K,Ferber S,McCulloch W,Thompson JA

    更新日期：2006-06-01 00:00:00

  • An Analysis of Staging and Treatment Trends for Upper Tract Urothelial Carcinoma in the National Cancer Database.

    abstract：BACKGROUND:The purpose of this study was to analyze contemporary trends for diagnosis and treatment of upper tract urothelial carcinoma (UTUC). PATIENTS AND METHODS:We identified all cases of UTUC in the National Cancer Database (NCDB) between 2004 and 2013. Data comprising tumor, patient, and facility factors were ex...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2018.01.015

    authors： Browne BM,Stensland KD,Moynihan MJ,Canes D

    更新日期：2018-08-01 00:00:00

  • Oncologic Outcomes in Young Adults With Kidney Cancer Treated During the Targeted Therapy Era.

    abstract：BACKGROUND:The objective of this study was to determine the outcomes of young adults with kidney cancer treated during the targeted therapy era and evaluate the impact of young age on survival. MATERIALS AND METHODS:We reviewed the records from 445 patients younger than 55 years with kidney cancer at a single institut...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.09.012

    authors： Sierra PS,Cordeiro MD,Albuquerque EV,Bastos DA,Bonadio RC,Sarkis AS,Cavalcante A,Pontes J Jr,Coelho RF,Nahas WC

    更新日期：2020-04-01 00:00:00

  • Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.

    abstract：BACKGROUND:Everolimus is an approved agent for use after disease progression with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) in patients with metastatic renal cell carcinoma. With recently published trials showing efficacy of nivolumab and cabozantinib in the second-line therapy...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2015.12.011

    authors： Patel SB,Stenehjem DD,Gill DM,Tantravahi SK,Agarwal AM,Hsu J,Vuong W,Pal SK,Agarwal N

    更新日期：2016-04-01 00:00:00

  • Spontaneous intraperitoneal perforation of the bladder: a late complication of radiation therapy for prostate cancer.

    abstract：:The spontaneous intraperitoneal rupture of the urinary bladder is an extremely rare and life-threatening event. Often, there are difficulties in establishing the diagnosis. A patient with spontaneous perforation of the urinary bladder, 17 years after successful treatment of an adenocarcinoma of the prostate by pelvic ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2007.n.006

    authors： Ketata S,Boulaire JL,Al-Ahdab N,Bargain A,Damamme A

    更新日期：2007-03-01 00:00:00

  • The R.E.N.A.L. nephrometric nomogram cannot accurately predict malignancy or aggressiveness of small renal masses amenable to partial nephrectomy.

    abstract：INTRODUCTION/BACKGROUND:The prediction of histology of SRM could be essential for their management. The RNN is a statistical tool designed to predict malignancy or high grading of enhancing renal masses. In this study we aimed to perform an external validation of the RNN in a cohort of patients who received a PN for SR...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2014.02.003

    authors： Antonelli A,Furlan M,Sandri M,Minervini A,Cindolo L,Parma P,Zaramella S,Porreca A,Vittori G,Samuelli A,Dente D,Berardinelli F,Raspollini MR,Serni S,Carini M,Terrone C,Schips L,Simeone C

    更新日期：2014-10-01 00:00:00

  • Sociodemographic Disparities in the Nonoperative Management of Small Renal Masses.

    abstract：BACKGROUND:Local tumor ablation (LTA) and expectant management (EM) represent competing treatment modalities for patients with small renal masses (SRMs) who are unfit for surgery. We examined the potential social discrepancies in the access of LTA and EM. MATERIALS AND METHODS:A total of 1860 patients with cT1a kidney...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2015.10.011

    authors： Trudeau V,Larcher A,Sun M,Boehm K,Dell'Oglio P,Meskawi M,Sosa J,Tian Z,Fossati N,Briganti A,Karakiewicz PI

    更新日期：2016-04-01 00:00:00

  • Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?

    abstract：BACKGROUND:In recent years, new-onset hypothyroidism was extensively reported in patients receiving sunitinib for malignancy. Effects of sunitinib on serum lipids are not described, however a hyperlipidemic state is commonly observed in hypothyroid patients. Here we report about the incidence and severity of hyperchole...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2014.08.009

    authors： Tassi R,Baldazzi V,Lapini A,Carini M,Mazzanti R

    更新日期：2015-04-01 00:00:00

  • Prognostic Significance of Preoperative Serum Lactate Dehydrogenase in Upper Urinary Tract Urothelial Carcinoma.

    abstract：BACKGROUND:Upper urinary tract urothelial carcinoma (UUTUC) is one of the uncommon malignancies lacking of prognostic indicators. Lactate dehydrogenase (LDH) has been demonstrated to correlate with clinical outcomes in human cancers. In this study, we aimed to evaluate the prognostic implication of the preoperative LDH...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.01.003

    authors： Zhang XK,Zhang ZL,Lu X,Yang P,Cai MY,Hu WM,Yun JP,Zhou FJ,Qian CN,Cao Y

    更新日期：2016-08-01 00:00:00

  • What Have Patients Been Hearing From Providers Since the 2012 USPSTF Recommendation Against Routine Prostate Cancer Screening?

    abstract：BACKGROUND:In this study we aimed to determine the relationship between prostate-specific antigen (PSA)-related information obtained from the provider and PSA test uptake. With recent focus on patient-provider communication (PC) and the guidelines recommending against PSA tests for prostate cancer (PCa), PC regarding t...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2017.05.002

    authors： Haider MR,Qureshi ZP,Horner R,Friedman DB,Bennett C

    更新日期：2017-12-01 00:00:00

  • Stem cell origin of testicular seminoma.

    abstract：INTRODUCTION:A major question concerning cancer is its cells of origin. We hypothesized that distinct cancer subtypes arise from unique cancer-initiating cells. By performing a microarray meta-analysis of seminomas and spermatogonial stem cells, we investigated a putative cell of origin for seminoma. MATERIALS AND MET...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,meta分析

    doi：10.1016/j.clgc.2013.04.015

    authors： Som A,Wen S,Tu SM

    更新日期：2013-12-01 00:00:00

  • Upper Urinary Tract Tumors: Variant Histology Versus Urothelial Carcinoma.

    abstract：PURPOSE:To evaluate stage at presentation and cancer-specific mortality (CSM) in upper urinary tract tumors according to histologic subtype. METHODS:Within the Surveillance, Epidemiology, and End Results registry (SEER, 2004-2016), we identified patients with upper urinary tract tumors with pure variant histology (UTV...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2020.11.004

    authors： Deuker M,Stolzenbach LF,Collà Ruvolo C,Nocera L,Tian Z,Roos FC,Becker A,Kluth LA,Tilki D,Shariat SF,Saad F,Chun FKH,Karakiewicz PI

    更新日期：2020-12-02 00:00:00

  • A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a SEER database analysis.

    abstract：BACKGROUND:Consistent with other data sets, our own institutional series suggests that survival in patients aged ≥ 75 years with metastatic renal cell carcinoma (mRCC) is inferior to that in patients < 75 years. We sought to confirm these trends through exploration of the Surveillance, Epidemiology and End Results (SEE...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2013.04.011

    authors： Nelson RA,Vogelzang N,Pal SK

    更新日期：2013-09-01 00:00:00

  • Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.

    abstract：INTRODUCTION/BACKGROUND:Targeted therapy has become the mainstay of treatment for mRCC. The efficacy of this therapy in the older population is poorly understood. PATIENTS AND METHODS:Data from patients with mRCC treated with first-line anti-VEGF therapy were collected through the International mRCC Database Consortiu...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2014.02.009

    authors： Khambati HK,Choueiri TK,Kollmannsberger CK,North S,Bjarnason GA,Vaishampayan UN,Wood L,Knox JJ,Tan MH,MacKenzie MJ,Donskov F,Rini BI,Heng DY,International mRCC Database Consortium.

    更新日期：2014-10-01 00:00:00

  • Clinical and Molecular Characteristics and Burden of Kidney Cancer Among Hispanics and Native Americans: Steps Toward Precision Medicine.

    abstract：:Cancer disparities in Native Americans (NAs) and Hispanic Americans (HAs) vary significantly in terms of cancer incidence and mortality rates across geographic regions. This review reports that kidney and renal pelvis cancers are unevenly affecting HAs and NAs compared to European Americans of non-Hispanic origin, and...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clgc.2018.01.006

    authors： Batai K,Bergersen A,Price E,Hynes K,Ellis NA,Lee BR

    更新日期：2018-06-01 00:00:00

  • Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma.

    abstract：BACKGROUND:Combination platinum chemotherapy is standard first-line therapy for metastatic urothelial carcinoma (mUC). Defining the platinum response biomarkers for patients with mUC could establish personalize medicine and provide insights into mUC biology. Although DNA repair mechanisms have been hypothesized to medi...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2015.12.029

    authors： Mullane SA,Werner L,Guancial EA,Lis RT,Stack EC,Loda M,Kantoff PW,Choueiri TK,Rosenberg J,Bellmunt J

    更新日期：2016-08-01 00:00:00

  • Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.

    abstract：BACKGROUND:Piritrexim is reported to have a response rate of 38% in patients with chemotherapy-naive disease and 23% for second-line therapy after chemotherapy failure. We report the results of a multiinstitutional, open-label, 2-stage, phase II study that further evaluates oral piritrexim in patients with urothelial c...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.3816/CGC.2008.n.005

    authors： Lassiter LK,Tummala MK,Hussain MH,Stadler WM,Petrylak DP,Carducci MA

    更新日期：2008-03-01 00:00:00

  • Efficacy of Immediate Postoperative Instillation of Chemotherapy for Primary Non-Muscle-Invasive Bladder Cancer in Real-World Clinical Practice.

    abstract：BACKGROUND:Non-muscle-invasive bladder cancer (NMIBC) can be treated using transurethral resection (TUR), but high incidence of intravesical recurrence remains a clinical challenge. Single immediate postoperative instillation of chemotherapy (IPIOC) is controversial for NMIBC patients with intermediate recurrence risk....

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.05.028

    authors： Murakami K,Hamada A,Teramoto Y,Matsumoto K,Kita Y,Saito R,Yamasaki T,Matsui Y,Inoue T,Ogawa O,Kobayashi T

    更新日期：2019-10-01 00:00:00

  • A Systematic Review and Network Meta-analysis of Novel Androgen Receptor Inhibitors in Non-metastatic Castration-resistant Prostate Cancer.

    abstract：BACKGROUND:Among men with high-risk non-metastatic castrate-resistant prostate cancer (nmCRPC), we used network meta-analysis to compare non-steroidal anti-androgens (NSAAs) and stratified class-level meta-analysis to identify subgroups with particular benefit from NSAAs with androgen deprivation therapy versus androge...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clgc.2020.02.005

    authors： Hird AE,Magee DE,Bhindi B,Ye XY,Chandrasekar T,Goldberg H,Klotz L,Fleshner N,Satkunasivam R,Klaassen Z,Wallis CJD

    更新日期：2020-10-01 00:00:00

  • Role of Inflammation in the Perioperative Management of Urothelial Bladder Cancer With Squamous-Cell Features: Impact of Neutrophil-to-Lymphocyte Ratio on Outcomes and Response to Neoadjuvant Chemotherapy.

    abstract：BACKGROUND:Neutrophil-to-lymphocyte ratio (NLR) might reflect an increased neutrophilic inflammatory response, and urothelial tumors with squamous-cell features (SqD) have been linked to inflammation. We hypothesized that NLR could be prognostic in these patients. PATIENTS AND METHODS:In patients with SqD muscle-invas...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2017.01.024

    authors： Buisan O,Orsola A,Oliveira M,Martinez R,Etxaniz O,Areal J,Ibarz L

    更新日期：2017-08-01 00:00:00

  • Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.

    abstract：INTRODUCTION:Pembrolizumab has been approved in the United States (US) for the first-line treatment of patients with advanced or metastatic urothelial carcinoma, who are ineligible for cisplatin-containing chemotherapy and with tumors expressing programmed death-ligand 1 (PD-L1) (Combined Positive Score ≥ 10), or ineli...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2020.07.006

    authors： Hale O,Patterson K,Lai Y,Meng Y,Li H,Godwin JL,Homet Moreno B,Mamtani R

    更新日期：2020-07-16 00:00:00

  • The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.

    abstract：BACKGROUND:Abiraterone and enzalutamide are 2 novel androgen receptor (AR)-targeting therapies that improve survival in patients with metastatic castration-resistant prostate cancer. The factors that predict abiraterone and enzalutamide response are lacking. The objective of the present study was to determine whether t...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.03.021

    authors： Hung J,Taylor AR,Divine GW,Hafron JM,Hwang C

    更新日期：2016-10-01 00:00:00

  • Prostate Cancer in Patients With High Prostate-Specific Antigen Levels but Otherwise Very-Low-Risk Disease Behaves Like Prostate Cancer in High-Risk Patients.

    abstract：INTRODUCTION:Rarely, patients with prostate cancer present with prostate-specific antigen (PSA) scores > 20 ng/mL but with otherwise very-low-risk disease. Oncologists have debated whether the malignancies in these patients behave more comparably to low-risk or high-risk disease. Our objective was to elucidate the beha...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.10.003

    authors： Gestaut MM,Pruszynski JE,Swanson GP

    更新日期：2017-08-01 00:00:00

  • Unravelling Adrenal Oncocytic Neoplasm.

    abstract：:Oncocytic neoplasms are rare tumors arising in the adrenal glands and usually considered as nonfunctional and benign. We report 4 cases of adrenal oncocytic neoplasm. The paucity of literature describing this entity increases the chance for misdiagnosis. Confirmatory diagnosis is by tissue sampling with adrenalectomy ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clgc.2018.10.011

    authors： Virarkar M,Patnana M,Vikram R,Bhargava P,Birkenfeld E,Sagebiel T

    更新日期：2019-02-01 00:00:00

  • Fourteen-Core Systematic Biopsy That Includes Two Anterior Cores in Men With PI-RADS Lesion ≥ 3 is Comparable With Magnetic Resonance Imaging-ultrasound Fusion Biopsy in Detecting Clinically Significant Prostate Cancer: A Single-institution Experience.

    abstract：INTRODUCTION:Magnetic resonance imaging (MRI)-ultrasound fusion targeted prostate biopsy (FB) has been advocated by many experts as a replacement for the standard template biopsy. Herein, we compared pathology results and cancer detection rates of FB with our standard 14-core systematic prostate biopsy (SB) that includ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2020.09.006

    authors： Sterling J,Smith K,Farber N,Nagaya N,Jang TL,Singer EA,Sadimin E,Kim IY

    更新日期：2020-10-13 00:00:00

  • Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT).

    abstract：BACKGROUND:The objective of this study was to evaluate differences in tolerability in patients with metastatic castration-resistant prostate cancer treated with enzalutamide (ENZA) or abiraterone acetate plus prednisone (AA+P). PATIENTS AND METHODS:This was a phase IV, prospective, open-label, multicenter, real-world ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2019.07.017

    authors： Shore ND,Saltzstein D,Sieber P,Mehlhaff B,Gervasi L,Phillips J,Wong YN,Pei H,McGowan T

    更新日期：2019-12-01 00:00:00